{"authors":["Associated Press"],"date_download":"2018-10-23 02:42:08","date_modify":"2018-10-23 02:42:08","date_publish":"2016-01-11 15:13:59","description":"WASHINGTON (AP) — The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marke...","filename":"data/vaneerConsumption/Highcourtwonthearappealover124Mdrugpenalty.json","image_url":"https://i.dailymail.co.uk/i/pix/m_logo_636x382px.png","language":"en","localpath":"/home/avsp_here/news-please-repo//data/2018/10/22/dailymail.co.uk/wires_ap_article-3394033_High-court-wont-hear-appeal-124M-drug-penalty_1540262528.html","title":"High court won't hear appeal over $124M drug penalty","title_page":"High court won't hear appeal over $124M drug penalty | Daily Mail Online","title_rss":"NULL","source_domain":"dailymail.co.uk","text":"High court won't hear appeal over $124M drug penalty\nWASHINGTON (AP) — The Supreme Court won't hear an appeal from a Johnson & Johnson subsidiary assessed more than $124 million in penalties for deceptive marketing of an anti-psychotic drug.\nThe justices on Monday let stand a lower court ruling that said Janssen Pharmaceuticals, Inc. should pay the penalties for violations of South Carolina law.\nIn 2011, a state trial court ordered the drug maker to pay $327 million, saying Janssen broke the law by downplaying to doctors the links between diabetes and Risperdal and by improperly claiming the drug was safer than competing medications. South Carolina's supreme court reduced the penalty because of the state's three-year statute of limitations on such cases.","url":"https://www.dailymail.co.uk/wires/ap/article-3394033/High-court-wont-hear-appeal-124M-drug-penalty.html"}
